1. US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®). (2nd December 2020) Authors: Naseer, Shabnam; Weinstein, Edward A; Rubin, Daniel B; Suvarna, Kalavati; Wei, Xiaohui; Higgins, Karen; Goodwin, Avery; Jang, Seong H; Iarikov, Dmitri; Farley, John; Nambiar, Sumathi Journal: Clinical infectious diseases Issue: Volume 72:Number 12(2021) Page Start: e1103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗